86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details


臨床試験数 : 1,181 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-002131-34-NL
(EUCTR)
29/07/201505/03/2015A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensionA Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.
MedDRA version: 18.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Code: GS-4997 2 mg
INN or Proposed INN: Not available
Product Code: GS-4997 6 mg
INN or Proposed INN: Not available
Product Code: GS-4997 18 mg
INN or Proposed INN: Not available
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Canada;Spain;Germany;Netherlands;Italy;United Kingdom
2EUCTR2014-002131-34-ES
(EUCTR)
18/05/201511/03/2015A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensionA Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.
MedDRA version: 17.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Code: GS-4997 2 mg
INN or Proposed INN: Not available
Product Code: GS-4997 6 mg
INN or Proposed INN: Not available
Product Code: GS-4997 18 mg
INN or Proposed INN: Not available
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Canada;Spain;Netherlands;Germany;Italy;United Kingdom
3EUCTR2014-002131-34-GB
(EUCTR)
15/05/201515/07/2015A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensionA Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.
MedDRA version: 18.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Code: GS-4997 2 mg
INN or Proposed INN: Not available
Product Code: GS-4997 6 mg
INN or Proposed INN: Not available
Product Code: GS-4997 18 mg
INN or Proposed INN: Not available
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Canada;Spain;Netherlands;Germany;Italy;United Kingdom
4EUCTR2014-002131-34-DE
(EUCTR)
07/05/201527/02/2015A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensionA Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.
MedDRA version: 18.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Code: GS-4997 2 mg
INN or Proposed INN: Not available
Product Code: GS-4997 6 mg
INN or Proposed INN: Not available
Product Code: GS-4997 18 mg
INN or Proposed INN: Not available
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Canada;Spain;Netherlands;Germany;Italy;United Kingdom
5EUCTR2014-002131-34-IT
(EUCTR)
09/04/201515/01/2016A clinical trial with GS-4997 in Subjects with Pulmonary Arterial HypertensionA Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and toxin use, or human immunodeficiency virus (HIV) infection.
MedDRA version: 18.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Code: GS-4997 2 mg
INN or Proposed INN: Not available
Product Code: GS-4997 6 mg
INN or Proposed INN: Not available
Product Code: GS-4997 18 mg
INN or Proposed INN: Not available
Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes
120Phase 2France;United States;Canada;Spain;Netherlands;Germany;United Kingdom;Italy